返回 
加入收藏
经不同静脉输液装置给予颅内恶性肿瘤患儿大剂量甲氨蝶呤的安全性比较
x
请在关注微信后，向客服人员索取文件
| 篇名： | 经不同静脉输液装置给予颅内恶性肿瘤患儿大剂量甲氨蝶呤的安全性比较 |
| TITLE： | Safety comparison of high-dose methotrexate via different intravenous infusion devices in pediatric patients with malignant brain tumors |
| 摘要： | 目的 比较颅内恶性肿瘤患儿经外周穿刺中心静脉导管（PICC）与植入式静脉输液港（TIVAP）给予大剂量甲氨蝶呤（HD-MTX）的安全性。方法回顾性分析本院2018年7月至2022年4月经PICC或TIVAP给予HD-MTX的颅内恶性肿瘤患儿病例，收集临床资料，比较两组患儿甲氨蝶呤（MTX）血药浓度、不良事件（包括药物不良反应和导管相关并发症）发生率及住院天数差异。应用多因素线性回归分析MTX血药浓度的影响因素。结果共纳入病例107例，其中PICC组65例、TIVAP组42例。TIVAP组给药后24hMTX血药浓度（C24h水平）显著高于PICC组（[126.87±61.99）μmol/Lvs.（102.45±48.77）μmol/L，P＜0.05]，给药后42hMTX血药浓度（C42h水平）与PICC组比较差异无统计学意义（P＞0.05）。多因素线性回归分析结果显示，经TIVAP给药与MTXC24h水平升高有关（P＜0.05）。两组间不良事件发生率与住院天数的差异均无统计学意义（P＞0.05）。结论经TIVAP给药可能出现MTXC24h水平升高，但不会提高不良事件发生率。在实施治疗药物监测的情况下，经TIVAP给予HD-MTX是较为安全的选择。 |
| ABSTRACT： | OBJECTIVE To compare the safety of high-dose methotrexate （HD-MTX） via peripherally inserted central catheter （PICC） and totally implantable venous access port （TIVAP） in pediatric patients with malignant brain tumors. METHODS Patients with malignant brain tumors who received HD-MTX via PICCs or TIVAPs in our hospital from July 2018 to April 2022 were retrospectively analyzed. Clinical data were collected to compare differences in blood concentration of methotrexate （MTX），the incidence of adverse events （including adverse drug reactions and catheter-related complications） and length of stay in hospital. Multivariate linear regression was applied to analyze the factors that influenced the blood concentration of MTX. RESULTS A total of 107 patients were included in the study，with 65 patients in the PICC group and 42 patients in the TIVAP group. Blood concentration of MTX at 24 h （C24 h） in TIVAP group was significantly higher than PICC group （[ 126.87±61.99） μmol/L vs. （102.45±48.77） μmol/L，P＜0.05）. There was no significant difference in blood concentration of MTX at 42 h （C42 h），compared with PICC group （P＞0.05）. Results of multivariate linear regression analysis showed that TIVAP was associated with the increase of C24 h（P＜0.05）. No significant differences were observed in the incidence of adverse events and the length of stay in the hospital between 2 groups （P＞0.05）. CONCLUSIONS Risk of adverse events is not increased，although the MTX C24 h level is elevated after administration of TIVAP. TIVAP is a safe choice for HD-MTX therapy with implementing therapeutic drug monitoring. |
| 期刊： | 2023年第34卷第07期 |
| 作者： | 续茜桥；时正媛；杨春静；王淑梅 |
| AUTHORS： | XU Xiqiao，SHI Zhengyuan，YANG Chunjing，WANG Shumei |
| 关键字： | 甲氨蝶呤；植入式静脉输液港；外周穿刺中心静脉导管；颅内恶性肿瘤；治疗药物监测；血药浓度；不良事件 |
| KEYWORDS： | methotrexate； totally implantable venous access port； peripherally inserted central catheter； malignant brain tumor； |
| 阅读数： | 530 次 |
| 本月下载数： | 3 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
